We performed a pooled analysis of the COMPARZ study assessing efficacy and safety of pazopanib versus sunitinib in treatment-naïve Chinese patients with locally advanced and/or metastatic renal cell carcinoma (a/mRCC). | Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma Pooled subgroup analysis from the randomized COMPARZ studies